Cure My Disease

Don't miss your cure!

 Log in / Sign up

Video and alert system aims to boost lifesaving heart failure prescriptions

NCT ID NCT06526988

Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests two simple tools to improve medication use in people with heart failure with reduced ejection fraction (HFrEF). One tool is a short animated video and checklist sent to patients before a clinic visit to encourage them to discuss their medications. The other is an alert that pops up for doctors during the visit, reminding them to prescribe or adjust key heart failure drugs. The goal is to see if these tools help more patients get the right medications at the right doses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient education video and clinician alert system
What this could lead to
If successful, this approach could help more heart failure patients receive life-saving medications at the right doses, improving their heart function and quality of life.
What could go wrong
The tools may not change prescribing habits as much as hoped, or benefits seen in earlier single-site studies may not hold across multiple health systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Clinician: * Clinician (MD, PA, NP) who practices in cardiology outpatient clinics * Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 10 patients with heart failure with reduced ejection fraction (HFrEF) Patient: * Age \> 18 years * LVEF \</=40% on most recent cardiology imaging study * Has a new or return clinic visit with an enrolled clinician within the next 7 days * Is missing at least one of the four classes of medications and does not have an allergy to that class: (1) beta blockers, (2) angiotensin receptor-neprilysin inhibitor, (3) aldosterone receptor antagonists, (4) sodium-glucose co-transporter Exclusion Criteria: Patient: * Has a left ventricular assist device * Under evaluation for or listed for transplant (or s/p transplant) * Glomerular filtration rate (GFR) less than 20 or on dialysis * On hospice care * Preferred language neither English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with reduced ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Sutter Health

    RECRUITING

    Walnut Creek, California, 94596, United States

  • University of Colorado

    RECRUITING

    Aurora, Colorado, 80045, United States

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84132, United States

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.